IL95377A - Pharmaceutical preparations for the treatment of ulcer disease containing histogenic history containing a tertiary hydroxylalkyl group and a number of new compounds of this type - Google Patents

Pharmaceutical preparations for the treatment of ulcer disease containing histogenic history containing a tertiary hydroxylalkyl group and a number of new compounds of this type

Info

Publication number
IL95377A
IL95377A IL9537790A IL9537790A IL95377A IL 95377 A IL95377 A IL 95377A IL 9537790 A IL9537790 A IL 9537790A IL 9537790 A IL9537790 A IL 9537790A IL 95377 A IL95377 A IL 95377A
Authority
IL
Israel
Prior art keywords
denotes
ethyl
compound
alkyl
hydroxy
Prior art date
Application number
IL9537790A
Other languages
English (en)
Hebrew (he)
Other versions
IL95377A0 (en
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of IL95377A0 publication Critical patent/IL95377A0/xx
Publication of IL95377A publication Critical patent/IL95377A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL9537790A 1989-08-16 1990-08-14 Pharmaceutical preparations for the treatment of ulcer disease containing histogenic history containing a tertiary hydroxylalkyl group and a number of new compounds of this type IL95377A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21018789 1989-08-16

Publications (2)

Publication Number Publication Date
IL95377A0 IL95377A0 (en) 1991-06-30
IL95377A true IL95377A (en) 1994-08-26

Family

ID=16585226

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9537790A IL95377A (en) 1989-08-16 1990-08-14 Pharmaceutical preparations for the treatment of ulcer disease containing histogenic history containing a tertiary hydroxylalkyl group and a number of new compounds of this type

Country Status (18)

Country Link
US (1) US5109003A (el)
EP (1) EP0413278B1 (el)
JP (1) JP2977242B2 (el)
KR (1) KR910004620A (el)
AT (1) ATE144900T1 (el)
AU (1) AU624987B2 (el)
CA (1) CA2023310A1 (el)
DD (1) DD298051A5 (el)
DE (1) DE69029069T2 (el)
DK (1) DK0413278T3 (el)
ES (1) ES2094132T3 (el)
GR (1) GR3021569T3 (el)
HU (1) HU207518B (el)
IE (1) IE902954A1 (el)
IL (1) IL95377A (el)
NZ (1) NZ234896A (el)
PT (1) PT95007A (el)
ZA (1) ZA906446B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5354756A (en) * 1993-01-12 1994-10-11 Cell Therapeutics, Inc. Olefin-substituted long chain xanthine compounds
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤

Also Published As

Publication number Publication date
JPH03163019A (ja) 1991-07-15
US5109003A (en) 1992-04-28
CA2023310A1 (en) 1991-02-17
DE69029069T2 (de) 1997-04-10
KR910004620A (ko) 1991-03-29
PT95007A (pt) 1991-04-18
NZ234896A (en) 1993-10-26
EP0413278A2 (en) 1991-02-20
GR3021569T3 (en) 1997-02-28
ATE144900T1 (de) 1996-11-15
HUT54688A (en) 1991-03-28
IE902954A1 (en) 1991-02-27
DE69029069D1 (de) 1996-12-12
ES2094132T3 (es) 1997-01-16
DD298051A5 (de) 1992-02-06
EP0413278B1 (en) 1996-11-06
HU905000D0 (en) 1991-01-28
AU624987B2 (en) 1992-06-25
DK0413278T3 (da) 1997-04-07
EP0413278A3 (en) 1992-05-06
HU207518B (en) 1993-04-28
IL95377A0 (en) 1991-06-30
JP2977242B2 (ja) 1999-11-15
AU6101890A (en) 1991-02-21
ZA906446B (en) 1991-05-29

Similar Documents

Publication Publication Date Title
JP3003333B2 (ja) アミノグリコシドにより誘発される腎毒性が実質的に減少されたアミノグリコシド組成物
EP1277738A1 (en) Condensed heteroaryl derivatives
CN111297866B (zh) 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
WO1996004914A1 (fr) Derive de triazine et medicament
EP0920868A1 (en) Remedy for erection failure comprising fused pyridazine compound
HU197842B (en) Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide derivatives
US5082845A (en) Therapeutic xanthine derivatives for the treatment of peptic ulcer disease
IL95377A (en) Pharmaceutical preparations for the treatment of ulcer disease containing histogenic history containing a tertiary hydroxylalkyl group and a number of new compounds of this type
JPH06192201A (ja) 置換フェノール、それらの製造方法および細胞増殖に起因する疾患の治療のためのそれらの使用
US4845102A (en) Therapeutic agent for the treatment of peptic ulcer disease
CA1318595C (en) 2-alkoxy-n-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
AU716992B2 (en) Hydroquinone derivative and pharmaceutical use thereof
JPS61502891A (ja) 新規の免疫に有効な化合物
JPH05262770A (ja) 化学的製法
JPH1129478A (ja) ジヒドロキノリン誘導体を含有する医薬組成物
JPH0559028A (ja) ベンゾチアゼピン誘導体、その塩類およびそれを含有する医薬組成物
JPH04368327A (ja) キヌクリジン化合物またはその塩を含有する抗潰瘍剤

Legal Events

Date Code Title Description
RH Patent void